Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution.
Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations.
Why choose Kindeva for your parental program
Large-scale sterile fill finish
The Bridgeton site supports vial, cartridge and prefilled syringe programs from clinical supply through commercial manufacturing. Operations run in Annex 1-compliant aseptic environments with isolator filling technology.
Advanced delivery platforms
Through established autoinjector platforms and scalable microneedle array patches, parenteral programs are transformed by Kindeva’s drug delivery expertise.
Designed for program progression
Our operations scale from clinical development to niche-commercial and large-scale manufacturing programs.
What you will find in the one-pager
This overview outlines Kindeva’s integrated pathway to parenteral delivery, including:
- Sterile injectable fill finish capabilities
- Autoinjector platform expertise
- Microneedle array patch manufacturing
- The integrated development pathway from formulation to final assembly
Learn how Kindeva brings control and confidence to parenteral programs.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Video tour | Explore Kindeva’s US manufacturing network
As a purpose-fueled, people-centric drug delivery CDMO, we are dedicated to advancing programs that help fast-track healthier tomorrows. Our US facilities play a vital role in delivering this commitment, providing specialized environments, technical depth and operational excellence that extend beyond manufacturing. Our US sites are strategically located and designed to support complex drug delivery programs […]
Learn More
Explore our world-class sterile injectable facility in Bridgeton, Missouri | Video tour
Spanning over 155,000 sq. ft. of dedicated aseptic operations space, our Bridgeton, MO facility brings together leading expertise, advanced automation and Annex 1-compliant isolator technology to help support growing global demand for sterile injectables. Designed to deliver excellence from floor to ceiling, Bridgeton seamlessly connects development and delivery through flexible fill finish infrastructure that helps […]
Learn More
PharmaSource podcast with Tommy Schornak
Today’s pharmaceutical companies must manage tight timelines and high demand for products, as well as shifting regulatory requirements and an increasingly complex global supply chain. How can contract development and manufacturing organizations (CDMOs) rise to this challenge and provide the support they need? In this podcast with PharmaSource, Tommy Shornak, Senior Vice President, Sterile Injectables, […]
Learn More
The bridge to uncompromising fill finish precision
Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]
Learn More
The bridge to the future of sterile injectables
Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]
Learn More
Your bridge to commercial sterile manufacturing
Sterile fill finish has changed. Annex 1 compliance and data transparency are no longer future considerations; they are the baseline. At the same time, programs are expected to move faster, scale seamlessly and maintain absolute control from the first clinical batch through commercial supply. Siloed models cannot keep up with the pace and control required […]
Learn More
Manufacturing more sustainable tomorrows for pulmonary care
The shift to more sustainable inhalers is gaining pace. As pressure grows to reduce their environmental impact, low-Global Warming Potential (GWP) propellants are becoming an important part of the future of metered dose inhaler (MDI) development. In this infographic, we explore the trends shaping that transition, and share how Kindeva is helping partners prepare for […]
Learn More
Parenteral precision: Annex 1-ready sterile fill finish by design
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]
Learn More
Beyond the bench: Aerosol analysis and the physics of MDI performance
Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.